Centre of Excellence for Peritoneal surface malignancy


Aster International Institute of Oncology (AIIO) takes pride in being certified as a Center of Excellence for the treatment of peritoneal surface malignancies, a particularly formidable group of cancers known for their aggressiveness.

Understanding Peritoneal Surface Malignancies:

Peritoneal surface malignancies are a group of highly lethal cancers that originate on the peritoneum, the thin membrane lining the abdominal cavity. These cancers typically emerge when tumors from various organs, including the appendix, rectum, colon, stomach, and ovaries, metastasize to the peritoneal surfaces.

Advanced Therapeutic Approaches:

AIIO employs state-of-the-art therapeutic interventions, notably Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). These advanced procedures have proven to be a transformative breakthrough in the treatment of peritoneal surface malignancies.

Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC):

Cytoreductive surgery involves the meticulous removal of visible tumors from the abdominal cavity. This is often complemented by HIPEC, a specialized form of chemotherapy where heated chemotherapy drugs are circulated within the abdomen during surgery. The combination of surgery and localized chemotherapy aims to eliminate remaining cancer cells, thereby increasing the likelihood of a curative outcome.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC):

PIPAC is another innovative technique employed at AIIO. It involves the application of chemotherapy in aerosolized form under pressure, creating a fine mist that evenly distributes within the abdominal cavity. PIPAC is particularly advantageous as it allows for a broader coverage and enhanced penetration of chemotherapy drugs into the affected areas.

Transforming Palliative Conditions into Curative Outcomes:

The implementation of these therapeutic modalities has been transformative for patients facing peritoneal surface malignancies. What was once considered a palliative condition, with limited treatment options and a grim prognosis, has now become a scenario where curative outcomes are achievable. The precision of CRS, combined with the targeted impact of HIPEC and PIPAC, has significantly improved the prospects for patients grappling with these aggressive malignancies.

Comprehensive and Multidisciplinary Care:

At AIIO, the treatment of peritoneal surface malignancies is delivered through a comprehensive and multidisciplinary approach. Our expert team collaborates closely, including surgical oncologists, medical oncologists, radiologists, pathologists, and support staff. This integrated approach ensures that patients receive the best possible care at every stage of their treatment journey.

Advancing Towards Hope and Cure:

With the recognition as a Center of Excellence for Peritoneal Surface Malignancy, AIIO remains committed to advancing research, refining treatment protocols, and offering hope to patients facing these challenging cancers. The certification underscores our dedication to achieving positive outcomes and enhancing the quality of life for individuals affected by peritoneal surface malignancies.

Aster International Institute of Oncology's designation as a Center of Excellence for Peritoneal Surface Malignancy signifies a pivotal stride in the fight against these formidable cancers. Our commitment to pioneering treatments, such as Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), reflects our unwavering dedication to transforming palliative conditions into curative possibilities. With a multidisciplinary team of experts, cutting-edge techniques, and a focus on comprehensive care, we stride confidently towards a future where peritoneal surface malignancies are met with hope, resilience, and the prospect of improved outcomes. At AIIO, we continue to advance the frontier of oncological care, bringing new possibilities and a renewed sense of optimism to those facing these challenging cancers.


At Aster Hospitals we provide the highest quality of care and a transformative experience for all your healthcare needs. With our network of multi-speciality hospitals, specialised doctors, and world-class technology, we bring global standards of medical care to our patients.

What is Peritoneal Surface Malignancy?

Peritoneal Surface Malignancy refers to cancers that develop on the lining of the abdomen, known as the peritoneum. These cancers often originate from tumors in various organs like the appendix, rectum, colon, stomach, ovaries, or others, spreading to peritoneal surfaces.

What therapeutic procedures are offered for Peritoneal Surface Malignancy?

AIIO specializes in groundbreaking treatments like Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). These procedures aim to transform palliative conditions into curative outcomes.

How does Cytoreductive Surgery with HIPEC work?

Cytoreductive Surgery involves removing visible tumors in the peritoneal cavity, followed by HIPEC, where heated chemotherapy is circulated in the abdomen to destroy any remaining cancer cells. This combined approach aims to improve treatment efficacy.

How does AIIO ensure comprehensive care for patients with these malignancies?

AIIO adopts a multidisciplinary approach, collaborating with experts from various specialties, including surgery, chemotherapy, and supportive care. This ensures that patients receive holistic and personalized treatment plans.

Why has AIIO been designated as a Center of Excellence?

AIIO has earned recognition as a Center of Excellence due to its expertise in treating peritoneal surface malignancies. The certification highlights our commitment to delivering advanced and comprehensive care for these challenging cancers.

Which cancers are addressed under Peritoneal Surface Malignancy?

Peritoneal Surface Malignancies can arise from various primary cancers, including those originating in the appendix, rectum, colon, stomach, ovaries, and other organs. AIIO's expertise covers a spectrum of these cancers.

What is the role of PIPAC in treating Peritoneal Surface Malignancy?

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a minimally invasive procedure involving the delivery of chemotherapy as an aerosol. It offers a targeted approach to treating peritoneal surface malignancies with fewer side effects.

Can Peritoneal Surface Malignancy be transformed from palliative to curative?

Yes, with advanced therapeutic interventions like Cytoreductive Surgery with HIPEC and PIPAC, AIIO endeavors to convert palliative conditions associated with peritoneal surface malignancies into curative outcomes, offering renewed hope to patients.